Amlodipine in Acute Coronary Syndrome and Coronary Artery Disease

Role in Acute Coronary Syndromes

Amlodipine is not a first-line agent during the acute phase of ACS, as beta-blockers remain the preferred anti-ischemic agent in the acute setting, reducing myocardial oxygen demand through heart rate and contractility reduction 1, 2
Calcium channel blockers like amlodipine should be reserved for patients with ongoing or recurrent ischemia despite adequate beta-blocker and nitrate therapy, or when beta-blockers are contraindicated 2

The American Heart Association recommends amlodipine for blood pressure control in hypertensive patients with established CAD, as it provides 24-hour blood pressure control with once-daily dosing, maintaining anti-ischemic effects throughout the dosing interval 3, 4
Amlodipine reduces myocardial oxygen demand through afterload reduction and coronary vasodilation, and slows progression of carotid atherosclerosis independent of blood pressure effects 2

The American College of Cardiology recommends amlodipine as an excellent choice for blood pressure control in hypertensive patients with established CAD, and as an add-on therapy to beta-blockers for additional blood pressure control or persistent angina 5, 3, 4
Amlodipine is safe and effective in post-MI patients with ejection fraction ≥40%, and should be added to, not substituted for, beta-blockers and ACE inhibitors in this population 5

The European Society of Cardiology recommends ensuring foundational therapy with aspirin, high-intensity statin, beta-blocker, and ACE inhibitor or ARB, before considering amlodipine for blood pressure control or angina relief 1, 5, 3
Amlodipine should be started at 5 mg once daily and titrated to 10 mg once daily as needed for blood pressure or angina control, with full anti-ischemic effects maintained for 24 hours with once-daily dosing 2, 5

The American Heart Association recommends combination therapy with ACE inhibitors and amlodipine for blood pressure control in CAD patients, as it is more effective than either alone 5, 4
Beta-blockers have proven mortality benefit post-MI that amlodipine lacks, but amlodipine provides superior blood pressure reduction in some patients, particularly elderly patients with isolated systolic hypertension 5, 4

The American College of Cardiology recommends the combination of nebivolol with amlodipine as a safe and effective treatment strategy for patients with coronary artery disease, particularly when hypertension coexists or when additional blood pressure control beyond beta-blocker monotherapy is needed 6

The European Society of Cardiology suggests that beta-blockers and dihydropyridine calcium channel blockers are both preferred agents for hypertension in CAD patients, with amlodipine added when beta-blocker monotherapy fails to achieve blood pressure targets of 130/80 mmHg 6
The American Heart Association recommends that diabetic CAD patients receive nebivolol, which improves insulin sensitivity and has neutral metabolic effects, making it superior to atenolol or metoprolol in diabetic patients 6

The American College of Cardiology recommends ensuring aspirin, high-intensity statin, and ACE inhibitor or ARB are already prescribed before initiating beta-blockers, which remain first-line for chronic stable angina and should be initiated before adding calcium channel blockers 7
The European Society of Cardiology suggests that nebivolol is preferred over traditional beta-blockers in CAD patients due to its endothelial function benefits and metabolic neutrality 6

The American Heart Association warns that beta-blockers, including nebivolol, are contraindicated in vasospastic angina as they can cause coronary constriction through alpha-adrenoreceptor-mediated vasoconstriction 7, 8
The European Society of Cardiology advises that calcium channel blockers like amlodipine may have deleterious effects on outcome in heart failure patients and should be avoided unless needed for blood pressure or angina control 7, 9

The American College of Cardiology notes that both nebivolol and amlodipine can be used safely in mild-to-moderate renal impairment, unlike ranolazine or trimetazidine which are contraindicated when GFR <30 ml/min/1.73 m² 6